FOXO1 Inhibition with AS1842856 as a Chemotherapeutic for Glioblastoma Multiforme and Basal-like Breast Cancer

The University of Texas Rio Grande Valley Background
Due to poor survival rate associated with aggressive cancers like basal-like breast cancer (BBC) and glioblastoma multiforme (GBM), no current technology exists that can efficaciously treat BBC and GBM cancers.
Technology Overview
This technology is a targeted therapy for aggressive cancers: basal-like cancer (BBC) and glioblastoma multiforme (GBM). Treatment with AS1842856 was found to induce cell death in a set of cancer lines, BBC: BT 549 and MDA-MB-468 as well as GBM: LN229, DBTRG, A172 and LN18.
A set of cancer lines were treated with AS 1842856 as a therapy for BBC and GBM. Results provided evidence of reduced cell numbers, induction of apoptotic genes and induction of apoptosis by membrane permeability (PI staining) and membrane depolarization (Annexin V FITC staining) by flow cytometric analysis ().
Stage of Development
Prototyping and characterization.

Treatment of a series of cancer cell lines including BT 549, MDA-MB-468, DBTRG, A 172, LN 18, HCT116 and SW480 led to reduced colony formation.
Treatment of a series of cancer cell lines including BT 549, MDA-MB-468, DBTRG, A 172, LN 18, and HCT116 led to apoptotic gene induction.
Treatment induced apoptosis as assessed by flow cytometric analysis in BT549 and LN229 cancer cell lines.

Value Proposition
FOXO1 inhibition is proposed as a targeted therapy to treat aggressive cancers like BBC and GBM The therapy is effective by reducing cell number, induction of apoptotic genes, and induction of apoptosis

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More